Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - JMP Securities maintained its Market Outperform rating and $21.00 price target on DBV Technologies S.A (NASDAQ:DBVT) Thursday, citing progress in the company’s peanut allergy treatment development program. The stock has shown remarkable momentum, surging nearly 190% over the past six months, though InvestingPro data indicates the company is currently trading above its Fair Value.
The research firm highlighted that DBV Technologies has successfully initiated its COMFORT Toddlers safety trial on schedule, setting the stage for a Biologics License Application (BLA) submission for children aged 1-3 years in the second half of 2026. JMP views the trial as a "low-risk hurdle to approval" since it doesn’t require efficacy or adhesion endpoints for success. With a market capitalization of $246 million, DBVT faces some financial challenges, as InvestingPro analysis reveals the company is quickly burning through cash and operating with short-term obligations exceeding liquid assets.
JMP Securities assigned a 90% probability of success for Viaskin Peanut’s approval in toddlers, noting the limited clinical risk remaining in the development process. The firm expects higher annual pricing ($15,000 versus $10,000) and greater utilization (40% versus 25% peak penetration) in the 1-3 year age group compared to older children.
For children aged 4-7 years, data from the Phase 3 VITESSE trial is expected in the fourth quarter, with a BLA submission anticipated in the first half of 2026. The modified Viaskin Peanut patch still needs to meet its primary efficacy endpoint for approval in this age group.
JMP assigned Viaskin Peanut a 70% probability of success in 4-7-year-olds due to "additional clinical risk in VITESSE," according to the research note.
In other recent news, DBV Technologies has been the subject of various analyst assessments and updates on its ongoing projects. Citizens JMP increased its price target for DBV Technologies to $21.00, citing positive developments in the company’s Viaskin Peanut product, including favorable safety and efficacy data for young children and a significant audience interest at a recent medical conference. Additionally, DBV Technologies has reached an agreement with the FDA regarding the Phase 3 VITESSE trial, which will meet safety requirements, eliminating the need for a previously planned safety study. H.C. Wainwright also raised its price target to $16.00, highlighting the encouraging data from studies involving the company’s EPIT platform and the strategic regulatory alignment for their Viaskin Peanut product.
On the other hand, Goldman Sachs reinstated coverage of DBV Technologies with a Sell rating and a price target of EUR1.30, expressing concerns over the company’s strategy to commercialize its product independently and the potential for significant share dilution following the Phase 3 VITESSE trial results. Despite these concerns, JMP Securities maintained its Market Outperform rating with a $10.00 price target, emphasizing the anticipated progress in the company’s clinical trials and its strategic plans to address peanut allergies in children. DBV Technologies is expected to submit its Biologics License Application for the 4-7 age group in the first half of 2026, with plans for the younger demographic submission in the second half of 2026. These developments collectively underscore the mixed outlook from analysts regarding DBV Technologies’ future performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.